A phase II trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a trial of the Eastern Cooperative Oncology Group (E1303)

BACKGROUND: Bortezomib, an inhibitor of the 26S proteasome and NF-κB, may have antitumor activity in adenoid cystic carcinoma (ACC). Preclinical studies have shown synergy between bortezomib and doxorubicin. METHODS: Eligibility criteria included incurable ACC, any number of prior therapies but with...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Argiris, Athanassios, Ghebremichael, Musie, Burtness, Barbara, Axelrod, Rita S., Deconti, Ronald C., Forastiere, Arlene A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2011
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3135694/
https://ncbi.nlm.nih.gov/pubmed/21246525
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.25852
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados